Clinical Trial: Study of QLS1410 in the Treatment of Primary Aldosteronism.

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550465) titled 'Study of QLS1410 in the Treatment of Primary Aldosteronism.' on April 19.

Brief Summary: This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of QLS1410 versus placebo, on the reduction of Seated Blood Pressure (SBP) in participants >= 18 years of age with Primary Aldosteronism (PA) with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics.

QLS1410 (or placebo) will be administered once daily, up-titrated after 2 weeks or 4 weeks based on clinical response and tolerability.

Stud...